Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG PENFILL versus SEMGLEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG PENFILL versus SEMGLEE.
NOVOLOG PENFILL vs SEMGLEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production via binding to insulin receptors, activating the insulin receptor tyrosine kinase cascade.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
Subcutaneous injection, 0.2 units/kg/day initially, adjusted based on blood glucose levels. Typical maintenance dose: 0.5-1 unit/kg/day.
None Documented
None Documented
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
18.3 hours; reflects protracted absorption from subcutaneous depot, enabling once-daily dosing
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Renal (30-80% as intact insulin); fecal (negligible)
Category C
Category C
Insulin Analog
Insulin Analog